4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol...
Transcript of 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol...
![Page 1: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/1.jpg)
Logo
177Lutetium-DOTA TATE Treatment of inoperable GEP NETs
Dr. Augusto Llamas-Olier. Nuclear medicine department. Instituto Nacional de Cancerologia. Bogota, Colombia.Dr. Maria Cristina Martínez*, Dr. Alfonso Lozano**
and Dr. Augusto Llamas-Olier*. *Nuclear Medicine and **Diagnostic Imaging Departments. Instituto Nacional de Cancerologia. Bogota, Colombia Nuclear medicine department.
Instituto Nacional de Cancerologia. Bogota, Colombia.
![Page 2: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/2.jpg)
• Patient: 50-year old female
• Clinical history: the patient was diagnosed with awell-differentiated neuroendocrine carcinoma of thepancreas with liver metastases and extensive tumorinvolvement of mediastinal and retroperitoneal lymphnodes.
![Page 3: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/3.jpg)
Logo
Subcarinal (A) and retrocrural (B) lymph node involment
A B
![Page 4: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/4.jpg)
Logo
Retroperitoneal (C) lymph node involvement and tumor mass (D) in head of pancreas
C D
![Page 5: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/5.jpg)
Baseline somatostatin receptor scintigraphyIndium-111 DTPA- Phe1-octreotide Activitiy: 5 mCi
Digitized MIP images obtained from a hard copy provided by the patient. The study was performed in an external institution.
There is extensive abnormal uptake in intrathoracic and retroperitoneal lymph nodes.
![Page 6: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/6.jpg)
Logo
• The tumor was considered inoperable by the board of neuroendocrine tumors treatment and palliative treatment was approved with 600 mCi of Lu-177 DOTA TATE divided in 200-mCi cycles every 6-10 weeks.
![Page 7: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/7.jpg)
Aug/09 Feb/10Dec/09Oct/09Dosimetry3,4 mCiANT 48 h
Post therapy scan 150 mCiANT 24 h
Post therapy scan 200 mCiANT 24 h
Post therapy scan 200 mCiANT 24 h
Interval response to therapy. Baseline dosimetry scan (A) obtained with a low dose of the radioligand. There issignificant interval change between the first (B) and second (C) post therapy scans obtained with a 3-mo difference.Further response is noticed in the final post therapy scan, obtained almost 6 months after the start of treatment.
A B C D
![Page 8: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/8.jpg)
99mTc-Hynic-Tyr3-octreotide. Selected coronal and sagital half-body SPECT images obtained at 4 hours post injection.
End of treatment. After three therapy doses of 177Lu-DOTA TATE there is residual focal uptake in the head of the pancreas. Significance reduction of uptake in retroperitoneal lymph nodes is noted.
![Page 9: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/9.jpg)
Baseline 6 mo. after last dose
CT follow up. The baseline lesion in the head of the pancreas is no longer evident at 6 months post therapy. Residual retroperitoneal lymph nodes are less than 1 cm.
![Page 10: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/10.jpg)
09-03-1006-02-09
Comparison between end of treatment (Feb/09) and 13 mo. follow upMRI. Interval disappearance of retroperitoneal lymph nodes is noted.
![Page 11: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/11.jpg)
• A significant response to treatment was evident after only two cycles of 177Lu-DOTA TATE.
• At the end of treatment the final response was deemed partial by RECIST standards, as there were residual paraaortic lymph nodes and a 3-cm mass in the head of the pancreas.
• 6 months after the last treatment cycle the mass at the head of the pancreas had disappeared and significant reduction in retroperitoneal lymph node involvement was noted.
Results
![Page 12: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/12.jpg)
12
Therapy with 177Lutetium DOTA TATE can be useful for inoperable, metastatic GEP NETs.
The rate of complete responses obtained by Kwekkeboom et al was only 2% in patients treated with 177Lu-DOTA TATE. They reported partial responses, minor responses, stable disease and progressive disease, respectively, in 26%, 19%, 35% and 15% of their patients.
Treatment tolerance was good, significant reduction of symptoms was obtained and 2-yr survival rate was 76 ± 16%.
Predictors of good response include: high uptake of lesions in somatostatin receptor scintigraphy and Karnofky’s performance status > 70%.
Predictors of poor prognosis include: massive liver involvement, bone metastases and Karnofky’s index < 70%.
Teaching Points
![Page 13: 4.Lu177 Treatment of GEP NETs - Human Health Campus...Kooij PP, et al. J Clin Oncol 2008;26:2124-2130. Title 4.Lu177 Treatment of GEP NETs [Compatibility Mode] Author paezd Created](https://reader035.fdocuments.us/reader035/viewer/2022071510/612f21af1ecc515869433f9b/html5/thumbnails/13.jpg)
ReferencesRadiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, De Herder WW, Feelders RA, et al. J Clin Oncol 2005;23:2754-2762.
Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3] Octreotate: Toxicity, Efficacy, and Survival. Kwekkeboom DJ, De Herder WW, Kam BL, Van Eijck CH, van Essen M,Kooij PP, et al. J Clin Oncol 2008;26:2124-2130.